Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 2/20 | 0.34 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.34 |
| ▸ | HAT1 | O14929 | 6/20 | 0.33 |
| ▸ | EP300 | Q09472 | 6/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17454414 | 0.88 | RAB9A (0.37) | EPHB3ALKBH1ROCK2ALOX15GFER | |
| SCHEMBL17437841 | 0.86 | ALDH1A1 (0.42) | EPHB3ALKBH1ROCK2ALOX15GFER | |
| SCHEMBL17452661 | 0.86 | HAT1 (0.35) | EPHB3HAT1EP300ROCK2JAK2 | |
| SCHEMBL17321419 | 0.85 | EIF4A3 (0.41) | EPHB3HAT1EP300ROCK2JAK2 | |
| SCHEMBL17452614 | 0.84 | ROCK2 (0.46) | HAT1EP300ROCK2PLA2G4A | |
| SCHEMBL23889140 | 0.81 | KMT2A (0.35) | ALKBH1ROCK2JAK2JAK1TSHR | |
| SCHEMBL17437905 | 0.81 | HPGD (0.42) | TSHR | |
| SCHEMBL20646896 | 0.80 | HAT1 (0.38) | HAT1EP300ROCK2PLA2G4A | |
| SCHEMBL20647180 | 0.80 | HAT1 (0.38) | HAT1EP300ROCK2PLA2G4A | |
| SCHEMBL23889125 | 0.80 | ROCK2 (0.36) | ROCK2JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | EPHB3 2687/4885ALKBH1 2319/4885HAT1 1976/4885 |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | EPHB3 2581/4885ALKBH1 2380/4885HAT1 1951/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | EPHB3 2581/4885ALKBH1 2380/4885HAT1 1951/4885 |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | EPHB3 1833/4885ALKBH1 3389/4885HAT1 3907/4885 |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | EPHB3 1833/4885ALKBH1 3389/4885HAT1 3907/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | EPHB3 2687/4885ALKBH1 2319/4885HAT1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.